Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Yokohama, Japan - September 12th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. has been selected for the project publicly solicited by the Japanese organization New Energy and Industrial Technology Development Organization (NEDO). Details in Japanese for local news in Japan. ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - Celltech Innovation Venture Studio Co., Ltd. (“CellTech Accelerator”), the first cell and gene therapy accelerator in Asia, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to accelerate the ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cell tech Innovation Venture Studio Co., Ltd. have entered into a business alliance. Details in Japanese for local news in Japan. Celltech Innovation Venture Studio Co., Ltd.（本社：台北、Founder & Chairman Johnny Yu、以下CellTech Accelerator）とMinaris Regenerative ...
NASHVILLE, Tenn., USA, and Yokohama, Japan - June 20th, 2024 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics ...
Yokohama, Japan - June 20th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cryoport, Inc. have entered into a business alliance. Details in Japanese for local news in Japan. Cryoport, Inc.（本社：テネシー州、CEO Jerrell W. Shelton、以下 Cryoport）とMinaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、再生医療等製品の輸送に関する業務提携契約を締結しました。 ...
Lüneburg and Ottobrunn, Germany, June 13, 2024 – Minaris Regenerative Medicine GmbH (Minaris), a leading contract development and manufacturing organization for cell and gene therapies, has implemented a digital Manufacturing Execution System (MES), the newest version of Werum PAS-X MES by Körber, at its German site in Ottobrunn near Munich. By doing so, Minaris is converting its production ...
Yokohama, Japan - June 4th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Myoridge Co., Ltd. have entered into a business alliance. Details in Japanese for local news in Japan. 株式会社マイオリッジ（本社：京都府京都市、代表取締役社長 牧田 直大、以下マイオリッジ）とMinaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、培地最適化による再生医療等製品の製造プロセス開発支援に関する業務提携契約を締結しました。 ...
With the recent FDA approval of LYFGENIA™, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product. The first commercial drug product was manufactured in early May. This confirms the capability of Minaris Regenerative Medicine as a commercial manufacturing CDMO. Allendale, NJ, USA, Wednesday 08 May 2024 – Minaris ...
Yokohama, Japan - March 14th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and VectorBuilder Inc. have entered into a business alliance. Details in Japanese for local news in Japan. Minaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、VectorBuilder Inc.（本社：Chicago, IL 60609, USA、最高科学責任者 Bruce Lahn, Ph.D.、以下 VectorBuilder）と業務提携を結んだことをお知らせします。 ...